Collaborative and Other Arrangements (Notes)

12 Months Ended

Dec. 31, 2020

Collaborative and Other Arrangements [Abstract]

Collaborative Arrangement Disclosure [Text Block]

COLLABORATIVE AND OTHER ARRANGEMENTS

    On February 3, 2017, we entered into two manufacturing and supply agreements ("MSA's"), (i) whereby Pfizer will manufacture and supply us with certain agreed upon products for an initial five-year term with a one-time two-year option to extend and (ii) whereby we will manufacture and supply Pfizer certain agreed upon products for a term of five or ten years depending on the product, also with a one-time two-year option to extend. The MSA's provide each party with mutually beneficial interests and both of the MSA's are to be jointly managed by both Pfizer and ICU. The initial supply price, which will be annually updated, is in full consideration for all costs associated with the manufacture, documentation, packaging and certification of the products.

Related-party revenue for goods manufactured for Pfizer under our Manufacturing and Supply Agreements with Pfizer was $78.2 million during 2018, and the cost of product manufactured by Pfizer for us under those agreements was $81.0 million during 2018.